Loading…
Loading…
BTAX does not currently pay a dividend.
See exactly how BTAX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BTAX and 80,000+ other tickers.
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart…
ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BIOX) ("Biostax" or "the Company"), a biopharmaceutical company focused on developing innovative immune restoration therapies, today announced its Board of Directors has approved and the Company intends to proceed with the voluntary delisting of its common stock from the OTC Pink marketplace. This strategic decision follows strong shareholder support, with 76.4% voting in favor of the delisting through a Joint Written Consent.
Orlando, FL, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biostax Corp ., (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, proudly announces its participation in the upcoming U.S. Business Action to End HIV Annual Coalition Meeting scheduled for November 30th, 2023, and the World AIDS Day Reception on December 1st, 2023.
Orlando, FL, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Influential Business Leader Roger “Craig” Suro.
Orlando, FL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Ms. Clay Caperton to its Board of Directors. Ms. Caperton stands as the esteemed founder and CEO of BOSACS Holding, LLC, boasting a rich history in the dynamic realm of sports management and has maintained a fervent dedication to the not-for-profit sector spanning over two decades. Her impactful journey has seen her contribute significantly to esteemed organizations, including the Bon Secours Foundation Board, Trinity Episcopal School Board of Trustees, Boys & Girls Clubs of Richmond, St. Mary's Episcopal School Board of Trustees, Soar365, and United Way Services of Greater Richmond.
ORLANDO, Fla., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX), a leading public company specializing in healthcare solutions, today announced a milestone in its transformative rebranding initiative. Both the State of Florida and FINRA have approved its name change from Immune Therapeutics, Inc. to Biostax and is now trading on OTC Pink Markets under the ticker symbol “BTAX”. This strategic shift signifies the company's planned pivot towards the international commercial application of substance abuse solutions and its commitment to innovative HIV treatment.